Share on StockTwits

Ovascience (NASDAQ:OVAS) Director Richard Aldrich bought 2,000 shares of Ovascience stock on the open market in a transaction dated Monday, June 23rd. The shares were purchased at an average cost of $8.81 per share, with a total value of $17,620.00. Following the completion of the transaction, the director now directly owns 526,445 shares in the company, valued at approximately $4,637,980. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Ovascience (NASDAQ:OVAS) opened at 9.025 on Thursday. Ovascience has a 52-week low of $5.509 and a 52-week high of $15.75. The stock has a 50-day moving average of $7.75 and a 200-day moving average of $8.89. The company’s market cap is $210.7 million.

Ovascience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.41) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.46) by $0.05. On average, analysts predict that Ovascience will post $-1.92 earnings per share for the current fiscal year.

OVAS has been the subject of a number of recent research reports. Analysts at HC Wainwright reiterated a “buy” rating on shares of Ovascience in a research note on Monday, May 12th. Separately, analysts at Oppenheimer initiated coverage on shares of Ovascience in a research note on Tuesday, April 29th. They set an “outperform” rating and a $11.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Ovascience to $16.00 in a research note on Thursday, April 3rd.

OvaScience, Inc, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.